• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Avanos Medical (AVNS) Rebounds Sharply, Is The Stock Above Fair Value?

    Simply Wall St·07/23/2026 16:30:32
    Listen to the news

    Avanos Medical (AVNS) continues to trade around $24.98, drawing attention from investors who are weighing its medical device portfolio against mixed financial metrics, including modest annual revenue growth and a reported net loss.

    See our latest analysis for Avanos Medical.

    Over the past year Avanos Medical’s share price return has moved sharply higher, with a year to date share price return of 123.43% and a 1 year total shareholder return of 106.28%. However, the 5 year total shareholder return shows a decline of 32.89%, which suggests that recent momentum contrasts with a weaker longer term experience.

    If the recent move in Avanos Medical has you reassessing healthcare opportunities, it may be worth widening your search through a screener focused on 41 healthcare AI stocks

    After Avanos Medical’s sharp rebound, investors are left weighing a company with a revenue base of $715.9 million and a loss of $74.4 million. Is the market being too cautious, or not cautious enough, as valuation comes into focus?

    Price to sales of 1.6x: Is it justified?

    Avanos Medical currently trades on a P/S ratio of 1.6x, which the data flags as expensive relative to an estimated fair P/S of 1.2x, even though the stock sits at $24.98 and has recently rebounded strongly.

    The P/S ratio compares the company’s market value to its annual revenue, so for Avanos Medical a 1.6x P/S means investors are paying $1.60 for every $1 of sales. For a business with $715.9 million of revenue and a reported loss of $74.4 million, P/S can be a useful reference point because earnings are not yet positive.

    On one side, Avanos Medical is described as good value relative to both the wider US Medical Equipment industry average P/S of 2.9x and a peer average of 2.7x. This suggests the market is not assigning it the same revenue multiple as many competitors. On the other side, compared with the estimated fair P/S of 1.2x, the current 1.6x level sits meaningfully higher, implying a valuation that could move closer to that lower reference point if sentiment or expectations change.

    Explore the SWS fair ratio for Avanos Medical

    Result: Price-to-sales of 1.6x (OVERVALUED)

    However, Avanos Medical still faces risks, including its current loss of $74.4 million and any setback in demand for its pain management or nutrition products.

    Find out about the key risks to this Avanos Medical narrative.

    Next Steps

    If this Avanos Medical story feels mixed to you, treat that as your cue to move quickly. Review the figures yourself and weigh the potential impact of its key risks, starting with the 1 important warning sign.

    Looking for more investment ideas beyond Avanos Medical?

    If Avanos Medical has sharpened your focus on opportunities, do not stop here. Use these focused stock lists to pressure test your ideas and uncover fresh candidates.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.